RetatrutideClinical Trials and pK Based Dosing Calculator

Retatrutide Dosing Math — Uniquely Sensitive Among GLP-1s

Retatrutide engages three receptors (GIP, GLP-1, and glucagon) at very unequal magnitudes, held continuously for a week instead of fired as brief pulses. That combination makes its dose ladder read differently than any other GLP-1.

Native GIP, GLP-1, and glucagon fire for a few minutes at a meal or during stress, then go quiet. Receptors evolved for that pulse pattern.

Retatrutide doesn't pulse. The molecule binds tightly to a blood-carrier protein (serum albumin) and releases slowly into the free fraction, so a single weekly injection holds receptor engagement around the clock. Half-life is six days.

By 1 mg, the GIP receptor sits at roughly 51% engagement — held 24 hours a day, for months. The same occupancy number reads completely differently as a five-minute mealtime spike versus a steady plateau across the entire week.

The dose required to reach engagement differs by an order of magnitude across the three receptors:

Retatrutide needs about 11% as much drug as native GIP for equivalent engagement. About 2.5× more drug than native GLP-1. About 3× more than native glucagon (Coskun 2022 binding constants¹²). Once engaged, all three signal at full strength — full agonists at all three¹⁵, not partial ones.

At 1 mg, retatrutide already engages more GIP receptor than tirzepatide does at its 15 mg ceiling¹⁴ — 51% versus 42%.

The receptor visual above reads through this same frame. The percentages aren't "how much effect comes out." They're how many of that receptor's molecules have a retatrutide on them at any moment, continuously, with no quiet period.

Microdose retatrutide isn't a weak version of the full dose. It's a structurally different signal mix — the GIP arm comes online well before the GLP-1 appetite arm or the glucagon arm. And the trial headlines all come from non-diabetic obese adults at one exposure; the same milligrams land differently on a leaner body, a metabolically healthier body, or one carrying more or less liver fat.

Clinical Trial Based Expectations at Each Dose

The interactive explorer based on the published pharmacokinetic data above walks every clinical dose through three distinct body types — non-diabetic obese, T2D obese, and lean metabolically healthy. Each dose produces a different mix of GIP, GLP-1, and glucagon signal, and the same milligrams land differently on different bodies.

Short version, for orientation:

• Microdose (0.3–1 mg) — GIP builds early and is nearly saturated by 1 mg. Liver activates first; visceral fat mobilizes early; appetite eases without forcing. Lighter or highly sensitive microdose-intent users may consider starting at 0.1 mg to test tolerance; the measured Phase 1 signal floor is 0.3 mg. Low weight or medication sensitivity can lower the start, but microdosing still requires microdose intent.
• Standard non-micro (1–5 mg) — 1 mg is the maintenance floor; 2–4 mg is where many standard non-micro calculator targets live before high-dose escalation. GIP is strong, GLP-1 climbs into meaningful satiety, and the glucagon arm builds.
• High-efficacy (6–9 mg) — GLP-1 and glucagon do the additional weight-loss work; GIP is plateaued. 9 mg is the routine high-dose ceiling in the based on the second highest dose cohort in the TRIUMPH clinical trials.
• Escalation (10–12 mg) — deliberate use above the routine high lane. The 8 → 12 step buys little extra mean weight loss in Phase II for substantial extra cost, but may matter for the deep-responder tail and liver/visceral-fat goals.

Below: how the same dose of retatrutide produces structurally different exposure and physiological response across body types.

Population Shift — Understanding Clinical Trial Cohorts

The trial population averaged 110 kg and BMI 38. If you're 70 kg and BMI 25 — or South Asian regardless of weight, or cardiovascularly fit at any weight — the same dose of retatrutide produces a structurally different exposure and a structurally different physiological response.

The shifts don't compose into a single multiplier. Each endpoint translates differently.

Drug exposure (PK). A lighter body has less blood to dilute the same dose. A 70 kg user at 1 mg ends up with about the drug concentration a 110 kg trial subject saw at 1.5 mg⁹. This part scales linearly with body weight.

Cardiovascular sensitivity. The big shift, and it isn't driven by drug concentration. Lean and metabolically healthy users operate on a fundamentally different cardiovascular engine (distinct cascade transduction states²²).

Retatrutide's Phase 1 SAD measured pulse-rate change at +7.6 bpm at 0.3 mg single dose, +10.3 bpm at 1 mg, +25.2 bpm at 4.5 mg, in healthy lean Asian subjects¹⁶. The obese trial population at chronic steady state saw +0.7 bpm at 1 mg. Drug-attributable cardiovascular response runs 25–50× larger in the lean cohort at matched dose.

In obese users, massive weight loss eventually lowers blood pressure and normalizes autonomic tone, which brings the heart rate back down. Lean users don't have 20 kg to lose, so they never get that compensatory offset. Their acute heart-rate peak becomes their chronic, sustained reality.

Hepatic response. Lean and obese populations have different rate-limiting steps. In the obese MASLD substudy, abundant baseline liver fat means even 1 mg drives 51% reduction; β-hydroxybutyrate (the marker of active hepatic fat oxidation) rises only modestly because insulin resistance dampens the readout. In healthy lean subjects, β-OHB stays flat at 1 mg and rises sharply at 4.5 mg — but there's no liver fat to deplete in the first place. Same dose, different signals across populations, because they have different biology to act on.

What this means for dosing outside the trial population:

• Lean, cardiovascularly responsive user (BMI 22–28, low resting HR, normal lipids): usually start at 0.3 mg if low-BMI, sub-160 lb, recomposition-focused, older, or dose-sensitive; otherwise 0.5 mg can be reasonable. That is a starting-dose decision, not a microdose ceiling. Dose bands compress. Moderate weight loss often appears at 2–4 mg rather than 4–8 mg; full weight-loss intensity may appear by 6–8/9 mg rather than 12 mg. The HR-as-cost framing matters more, not less. At 1 mg seeing +4 bpm raw, the cardiac BMR cost is 120–200 kcal/day — meaningful for body composition while still below standard obesity-trial maintenance doses.

• Lean South Asian phenotype. Higher chronotropic sensitivity than European-reference lean at matched body weight. The Phase 1 SAD cohort was 98% Asian, conducted in Singapore — those numbers describe this profile directly. Start at 0.3 mg for ordinary cautious entry; if the intent is true microdosing and the user is lighter or highly sensitive, the trace-start ladder can begin at 0.1 mg.

• High-baseline liver fat (MASLD), regardless of body size: 1 mg already produces meaningful hepatic effect. Climbing past 4 mg buys diminishing returns on liver fat (59% at 4 mg, 82% at 8 mg, 86% at 12 mg).

Retatrutide's Three Receptor Pathways Scale Differently by Dose

Two considerations sit underneath every titration decision.

Receptor occupancy at each dose stops climbing once a step has held for about three weeks. Plasma stabilizes; the dial-up is over.

What the body has adapted to runs slower, and not on one clock. The brainstem nausea-brake circuit needs the first 4–8 weeks of low-intensity firing to wire in²¹. Resting heart rate keeps drifting up through week 12–16 even when the dose itself hasn't changed. Liver fat reduction is still moving at week 48. Appetite hits about 95% of its long-run effect by week 24. Each axis has its own time-to-threshold and time-to-mature.

Side effects don't track the dose number. They track the gap between current receptor load and adapted load on the most sensitive axis. Nausea that hasn't quieted, resting HR still climbing two weeks after a step, dry mouth from suppressed intake, palpitations, sleep disruption — each one means the gap is still open.

Escalating while that gap is open stacks new shock on top of unpaid shock. Holding isn't failure; it's how the next step lands cleanly¹¹.

Fast vs. Slow Titration — The Impact on Side Effects & Tolerability

By 4 mg the GIP receptor is roughly 81% occupied. Climbing to 8 mg adds about 9 percentage points of GIPR engagement — essentially flat. What climbs sharply is GLP-1R engagement (about +18 points) and glucagon receptor engagement (about +5 points), the two arms that drive nausea, vomiting, and the cardiac response.

The GIPR brake circuit that buffers nausea works only if it has been firing alongside low GLP-1R load long enough to build connections to the GLP-1R nausea pathway²¹. Starting at 2 mg and stepping every four weeks gives that wiring time to form before the GLP-1R load gets large. Jumping 0 → 4 mg as the first dose hits the GLP-1R pathway at 23% engagement before the brake has had any chance to wire. Once that window closes, slowing down later cannot rebuild it — the low-intensity co-firing signal that strengthens the connection is gone.

Every GLP-1-engaging compound that has been tested rapid against slow titration shows the same pattern. Survodutide's Phase 2 trial recorded most of its discontinuations during fast escalation, and the sponsor redesigned the Phase 3 titration after that lesson. Tirzepatide's pivotal program built in 4-week holds per step from the start. The drug works at maintenance. The question is whether the user is still on it when they get there.

Dose Escalation Effects Body-Composition (Fat:Lean Loss Ratios)

Same drug, same final receptor engagement at maintenance, structurally different body composition by titration speed.

Waist circumference change ÷ weight change is a quasi-DEXA proxy. Above 1.0 means lost weight is concentrated in belly fat. Near or below 1.0 means it's dispersed across water, lean mass, and surface fat.

Within-pair, week 4.

The fast 8 mg arm wins on total weight (−5.3% vs −3.8%) and loses half the waist circumference per unit of weight. The slow 4 mg arm shows the opposite shape: less total weight, but what comes off is overwhelmingly belly fat.

Slow ramping keeps the user near caloric balance through the early weeks — low GLP-1 signal, normal food intake. Modest glucagon engagement preferentially mobilizes visceral fat, where glucagon-receptor density is highest.

Fast ramping forces caloric deficit through sustained nausea, food intake collapses, and the deficit pulls fuel from everywhere — water, lean mass, subcutaneous fat — proportionally less visceral.

The "extra" weight loss in fast-titration arms isn't extra fat. It's water, lean mass, and surface fat — the kinds you generally want to keep¹⁰.

GLP-1 and Glucagon Driven Heart Rate Increase Accelerates Weight Loss

The cardiac signal isn't only a cost. Each sustained 1 bpm of resting heart rate adds 30–50 kcal/day of cardiac muscle work⁷. At the trial's 12 mg dose (+9 bpm raw at 24 weeks), that's 300–450 kcal/day — a meaningful share of why higher doses lose more weight.

The fade from peak toward week 48 isn't receptor desensitization. Animal data confirms the receptor-level signal persists for at least six months at matched exposure. The decline is whole-system compensation — weight loss, baroreflex resetting, sympathetic adaptation. Users who don't lose substantial weight don't get that compensation. Their peak becomes their chronic reality, which is why the cost-per-bpm calculation matters even more for lean users.

Clinical Trial & pK Based Dosing Protocol for obese and high BMI individuals

0.5 mg is the practical default start. The directly measured Phase II obesity arm began at 1 mg, but the FoxAI dosing calculator uses 0.5 mg first so non-micro users still get a four-plus-step adaptation ladder instead of jumping straight into the trial arm.

The 1 → 1.5 → 2 → 2.5 → 3 → 3.5 → 4/5 mg build is where food noise quiets and weight loss begins. GI burden peaks here if titration is rushed.

By 6 → 8 → 9 mg, weight loss accelerates, the heart-rate climb becomes noticeable, and liver fat reduction picks up. 9 mg is the routine high ceiling in the FoxAI dosing calculator. 10–12 mg is for deliberate escalation, not the ordinary destination.

Published Data & pK Based Dosing Protocol for Lower BMI / Metabolically Healthier Populations

At 0.3–0.5 mg in this group, food noise may quiet, hepatic effects begin, and heart rate may climb a few bpm in the first week. Therapy from the start, not just a tolerance step.

The 0.5 → 1 mg build gets lower-BMI or lower-weight non-micro users to the standard maintenance floor without pretending the lower rungs are the destination. If results are limited by week 12 and side effects are quiet, 1–2 mg becomes the continuation range. Cardiac response can run above what the trial numbers predict at the same dose.

At 2.5 → 3 → 3.5 → 4/5 mg the standard non-micro effect is online for many lower-BMI users, and the cardiac threshold crosses earlier than in the trial population. Track resting heart rate weekly through this band.

6–9 mg is high-efficacy territory for this group, not a default target.

Two rules apply to both schedules.

Don't skip bridge rungs on the way up. The direct 4 → 8 mg jump is the clearest trial example of a gap the body doesn't adapt to — sustained 30–35% GI symptoms across 48 weeks while every other arm faded to single-digit prevalence by month 9. The FoxAI dosing calculator uses 5 and 6 mg bridge rungs before 8/9 mg for that reason.

Hold at least 4 weeks per step. Retatrutide's half-life is about six days; plasma at a new step doesn't stabilize for almost three weeks. A heart-rate or GI response at one dose can show up after you've already moved to the next.

At chronic steady state on a held dose, plasma oscillates only about 22% above the weekly average (peak-to-trough is 1.7×). The peak-concentration cost shows up in three specific places: the first dose, each titration step, and missed-then-redose. At chronic maintenance — same dose held more than 4 weeks — the peak-vs-average differential is muted; tolerability scales with average exposure rather than peak oscillation.

For microdose maintenance: 0.1 → 0.3 → 0.5 mg for lighter or highly sensitive microdose-intent users; 0.3 → 0.5 → 0.75 mg (final step if warranted) for many metabolic health, quiet food noise, or recomposition users; optional 1 mg for heavier 200+ lb microdose-intent users. Sensitivity alone does not define microdosing; it mainly lowers the start and slows escalation. The hold is the strategy, not a stop on the way to something higher.

Side effects, Monitoring, and Stopping Protocol

Side effects on retatrutide come from two distinct receptor sources.

GLP-1-class side effects — nausea, vomiting, diarrhea, slowed gastric emptying, and heart rate elevation. Heart rate climbs because GLP-1 directly stimulates the heart's pacemaker (sinoatrial node chronotropy¹⁹). Track GLP-1 receptor engagement.

These scale with dose, peak during titration, and partially adapt over time. Manageable with: slow titration, not skipping titration steps, eating smaller meals, anchoring intake on protein.

The 8 → 12 mg step adds substantial GLP-1 engagement (40% → 49%). Most of the additional GI cost at 12 mg comes from this, not from glucagon.

Glucagon-class side effects — dysesthesia (burning/tingling in extremities), cold extremities, sustained lipolysis-related effects, T4-to-T3 thyroid conversion suppression with associated fatigue. The glucagon arm also acts as a secondary contributor to the heart rate climb (multi-receptor composite chronotropy²⁰). Track glucagon receptor engagement.

These emerge at threshold doses: dysesthesia above 8 mg. The full glucagon-class spectrum doesn't appear at microdose because the peripheral nerves and subcutaneous fat haven't been engaged.

Two flags from this class deserve separate handling.

Sustained glucagon signaling can suppress active thyroid hormone production. Free T3 drops while TSH stays normal, so the standard thyroid panel misses it¹³. Users developing unexplained fatigue, brain fog, or cold intolerance should have Free T3 measured, not just TSH.

New-onset atrial fibrillation surfaces in real-world use at higher doses, but isn't pre-specified in the Phase 2 MedDRA capture template — the trial AE inventory under-reports it by design. Pre-existing AF or known structural cardiovascular disease is an explicit contraindication. For users at 6 mg and above with smartwatch ECG capability, monitor for irregular rhythm at each escalation.

Baseline panel before starting

A pre-injection panel makes every subsequent dose decision defensible. Without it, a rising heart rate at week 8 can't be distinguished from a drug effect.

• Resting heart rate and rhythm, recorded for a full week at baseline. ECG if any cardiac history.
• Fasting glucose, HbA1c, fasting insulin — the metabolic starting point.
• Lipid panel — Phase 2 obesity data showed 20% LDL reduction and triglyceride drops in line with weight loss.
• Thyroid panel including Free T3 — not just TSH. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication across the GLP-1 class.
• Liver enzymes, with imaging if MASLD is on the table.

Tracking on therapy

• Resting HR weekly through titration; biweekly at maintenance.
• Smartwatch ECG checks at each escalation when available, especially past 6 mg.
• Weight and waist circumference weekly, same conditions. Waist trend is the cleaner signal for visceral-fat response.
• Quarterly: fasting glucose, HbA1c, fasting insulin, lipid panel, liver enzymes.
• Free T3 if fatigue appears.

Stopping rules during titration

• Resting HR sustained more than +10 bpm above baseline for two consecutive weeks — hold at current dose until it settles.
• Unresolved GI distress from the previous step — extend the current step before increasing further. Do not stack.
• Dysesthesia at 8–12 mg — reducing to 4–6 mg attenuates it; reducing to 1–2 mg essentially eliminates it.
• New-onset irregular rhythm or smartwatch AF flag — hold dose, get a clinical ECG, do not advance until cleared.

The mid-range (4–6 mg) preserves most of the weight-loss effect — ≥17% at 48 weeks — without the full glucagon-class spectrum. Higher is not automatically better.

Stopping & maintenance

Retatrutide produces stronger regain pressure on discontinuation than semaglutide or tirzepatide. No published retatrutide withdrawal trial exists yet. The framework below is built from Phase 2 dose-response data plus published withdrawal trials of semaglutide (STEP-1 extension, STEP-4) and tirzepatide (SURMOUNT-4), with retatrutide-specific extrapolation called out where it occurs.

The four forces of regain

After stopping retatrutide, four mechanisms can pull weight back up. Three are class-shared; one is retatrutide-specific.

1. Appetite-suppression withdrawal. Gastric emptying returns to baseline; satiety signals fade. Drug washes out over about 30 days at the 6-day half-life. Food noise typically returns around week 3.

1. Lean-mass-driven BMR contraction. Any lean mass lost during the deficit lowers daily energy use unless training and protein rebuild it. Sema STEP-1 DXA showed 62:38 fat:lean; tirz SURMOUNT-1 DXA 75:25; retatrutide T2D DXA 63:37 with a provisional non-T2D pointer at 75–80:20–25 from TRIUMPH-4 conference quotes.

1. Hunger-hormone rebound + set-point defense. After major weight loss, hunger and energy-conservation signals can persist for about 12 months¹⁸. Plasma ghrelin during retatrutide treatment or withdrawal hasn't been measured. This layer is mechanism-inferred for retatrutide specifically.

1. Glucagon-axis signal loss — retatrutide-specific. Active liver fat oxidation and the preservation of resting metabolic rate fade within weeks of the last dose. Retatrutide doesn't actively raise metabolism; it stops it from crashing as you lose weight (adaptive thermogenesis offset²³). When the drug washes out, that metabolic defense drops. This is what makes stopping retatrutide structurally different from stopping sema or tirz.

The STEP-1 extension showed semaglutide users regaining about two-thirds of lost weight within 52 weeks of stopping. Retatrutide's curve is expected to be steeper given the fourth force. Phase 3 readouts through 2027 will measure it directly.

The taper

No known physical withdrawal syndrome exists. Stopping abruptly doesn't make you acutely sick.

Cold-turkey discontinuation may set up regain. Appetite returns as the drug washes out, lean mass is already reduced, and the glucagon-arm metabolic lift fades with no direct withdrawal data telling us how large that change is.

The purpose of tapering isn't receptor detox. It's behavioral and metabolic. A taper buys 8–12 weeks of lower-but-still-present appetite suppression in which to rebuild lean mass and lock in eating and training patterns that have to hold once the drug is gone.

The 2–4 mg maintenance band isn't trial-validated, but the receptor math supports it. The 8 mg arm captures 94% of the 12 mg arm's effect; the 4 mg arm engages GIP at 81%, GLP-1 at 26%, glucagon at 4.5% — meaningful signaling at all three receptors, sub-cardiac on glucagon. Maintenance logic from SURMOUNT-4 and STEP-4 supports the broader pattern that continued receptor signal lowers regain risk vs stopping.

Phase 1 — Maintenance hold. 8–12 weeks at 2–4 mg weekly. Stabilize at lower dose. Build training volume. Plan support.

Phase 2 — Step-down. 8–16 weeks, reducing 0.5 mg every 2–4 weeks. Assess regain signals at each step. Hold if weight drifts up.

Phase 3 — Off-drug or minimum effective. Ongoing. Either 0 mg, or 1–2 mg every 2 weeks for low-touch maintenance.

For retatrutide specifically, 4 mg looks like the floor that preserves the structurally distinctive features (active hepatic FAO, GIP-driven thermogenesis) without the high-dose costs.

Tracking the transition

Weight weekly, same conditions (morning, fasted, post-void). Waist circumference biweekly — visceral-fat trend tells you whether the glucagon-axis effect is holding or regressing. Resting heart rate biweekly; expect a 2–4 bpm drop through the taper as glucagon-driven cardiac stim fades. Strength (big-three lifts) tracked weekly — strength trend is the leading indicator of lean-mass preservation. Hunger on a 1–10 scale checked daily through weeks 3–6. Fasting glucose and lipids at weeks 4 / 12 / 24.

Weeks 1–2. Drug at therapeutic levels. Appetite quiet. Maintain training. Confirm support is in place.

Weeks 3–4. Gastric emptying normalizes. Food noise returns. RHR may drop 2–4 bpm. Hold protein discipline. Fiber-forward meals. Track hunger.

Weeks 5–8. Convergence window. Appetite returns, class-level regain curves matter, body is defending lower weight with less lean mass. Reta-specific ghrelin and REE data unmeasured. Highest-risk window. Don't miss resistance sessions. Tighten food structure before changing dose.

Weeks 8–16. With taper + training, weight may stabilize. Without, regain risk rises. Waist + DXA check at week 12. If regain >5%, evaluate low-dose restart.

If RHR drops more than 10 bpm or you experience dizziness, fainting, or chest discomfort, see a clinician. That's outside the expected pattern.

Support during the transition

The biggest lever is muscle preservation. ≥1.6 g/kg protein distributed across 3–4 meals daily, ≥3 g leucine per meal²⁴. Resistance training 3–5 sessions per week — compound lifts (squat, deadlift, press, row, pull-up), progressive overload from week 1 of the taper, not after. The active LEAN Mass RCT (NCT06885736) is testing resistance-training interventions specifically during GLP-1 discontinuation; no results yet.

Pharmacological adjuncts cover specific gaps that retatrutide was filling. They aren't proven replacements.

• Tesamorelin if waist, VAT, or liver markers drift. Pulsatile GH release reduces visceral adipose and liver fat²⁵; doesn't reproduce the GLP-1/GIP/glucagon triple-agonist effect. See Retatrutide Dual-Axis.
• MOTS-c if training output, fatigue, or insulin sensitivity worsen. Mitochondrial-derived peptide; activates AMPK²⁶. Post-retatrutide human protocol evidence is thin. See MOTS-c.
• NAD+ if fatigue or low intake fits. Cofactor layer for fat oxidation; demand rises as glucagon-driven oxidation fades. See Retatrutide + NAD+ Protocol.

If using an adjunct, start during Phase 1 of the taper rather than waiting until weight is moving the wrong direction.

When to restart vs stay off

Decision framework, not a prescription. Restart decisions belong with a clinician.

Red flags — evaluate low-dose restart:

• >5% weight regain over 8 weeks despite protocol adherence
• Visceral fat markers rebounding despite tesamorelin
• HbA1c drift above pre-drug baseline
• Strength declining month-over-month despite protein and session consistency

Green flags — stay off:

• Weight stable ±3 lb over 12 weeks
• Strength trending up
• Glucose and lipid panels stable or improving
• Subjective energy and food-noise levels manageable

If restart is indicated, lower-dose re-entry is usually more rational than returning to peak dose. The set-point biology behind the persistent-hormone-adaptation finding¹⁸ is a 12-month story. Some people need longer pharmacological assistance than a single cycle.

Clinical Data Limitations

Retatrutide is investigational. Phase 3 is reading out through 2026–2027.

• No DXA fat:lean data for non-diabetic obesity yet. TRIUMPH-4 manuscript pending. Tirzepatide's measured 75:25 fat-to-lean preservation ratio doesn't necessarily transfer.
• No published step-down maintenance protocol. Any high-to-mid-to-low taper rhythm is mechanism-derived, not measured.
• No head-to-head vs tirzepatide. TRIUMPH-5 (NCT06662383) will produce the first direct dose-matched comparison.
• No retatrutide-specific population PK by body weight. The lean-user math uses class analogy from semaglutide and tirzepatide PK literature, not direct retatrutide measurement.
• Long-term safety beyond Phase 2 (12 mg × 48 wk) is not yet characterized. TRIUMPH-Outcomes (n=10,000 cardiovascular and renal endpoints) is the chronic-duration trial.

The microdose case is the strongest evidence position in the GLP-1 class. The 1 mg arm of Phase 2 produced direct measurement. The high-dose long-term safety case carries materially more uncertainty than tirzepatide or semaglutide do at comparable durations.

FAQ

Related Topics

• Retatrutide Deep Dive — full mechanism, trial cohorts, body-composition data
• Retatrutide vs. Tirzepatide — direct comparison
• Retatrutide Dual-Axis Protocol — advanced stacking for recomposition
• Retatrutide + NAD+ Protocol — cofactor layer during active dosing
• GLP-1 Hub — broader GLP-1 family coverage
• GLP-1 Dosing Optimizer — interactive frequency calculator with plasma curves
• Full Reconstitution Calculator — all peptides, cocktails, custom BAC volumes
• GLP-1 Muscle Preservation — protect muscle during weight loss

References

¹ Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023: 10.1056/NEJMoa2301972 — Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity); per-arm-per-initial-dose split tables; HR Δ at 24 wk; AE temporal pattern (Figure S9); responder distributions.

² Hyperbolic saturation — receptor occupancy = [free drug] / ([free drug] + EC50). Standard Hill-equation pharmacology applied to retatrutide's free-drug Cav,ss and Coskun 2022 binding constants. The first 1 mg crosses the steepest portion of the GIP curve; subsequent dose increases produce diminishing returns. Retatrutide's GIP receptor binding constant is 16× lower (tighter) than tirzepatide's, which is why the GIP curve fills faster on retatrutide than the equivalent dose of tirzepatide would.

³ Tissue-threshold split — receptor density, downstream signal amplification, and per-tissue glucagon sensitivity differ across liver, visceral fat, sinus node, and subcutaneous fat. Thresholds derived from Phase 2 dose-response data and tissue-specific glucagon receptor pharmacology.

⁴ Downstream saturation / spare receptor — full physiological response often achieved at 10–20% receptor occupancy because the cell's downstream signaling pathway has its own ceiling. Standard receptor pharmacology principle, applied to incretin signaling.

⁵ White-fat futile calcium cycling — chronic GIPR engagement on white adipocytes triggers SERCA-mediated ER calcium leak; the pump runs continuously, burning ATP and forcing the cell to oxidize stored fat for fuel. Yu 2025 Cell Metabolism.

⁶ Sanyal AJ, et al. Retatrutide MASLD substudy. Nature Medicine 2024: s41591-024-03018-2 — 48-week MRI-PDFF liver fat reduction (51% at 1 mg, 86% at 12 mg); VAT and ASAT data; insulin and lipid panels; β-hydroxybutyrate as biomarker of hepatic fatty-acid oxidation.

⁷ Cardiac BMR cost — each 1 bpm of sustained resting HR adds 30–50 kcal/day from cardiac muscle work. Use raw HR Δ for this calculation, not placebo-subtracted (placebo arm shows real cardiovascular adaptation from weight loss + lifestyle counseling, so subtraction over-corrects for drug-attributable cost).

⁸ Eli Lilly press release, December 11, 2025 — TRIUMPH-4 Phase 3 results in obesity + osteoarthritis; 12 mg = 28.7% weight loss at 68 weeks. investor.lilly.com.

⁹ Population PK exposure shift by body weight — derived from class-analogous semaglutide and tirzepatide population-PK literature (Carlsson Petri 2018 Diabetes Therapy; Schneck 2024 CPT). Retatrutide-specific body-weight covariate not yet published; class analogy applied. A 70 kg user lands at approximately 1.4–1.6× the exposure of an 85 kg reference subject at the same nominal dose.

¹⁰ Within-pair titration analysis — Jastreboff 2023 supplementary tables S4 + S5, Figure 1A trajectory data, Figure S9 panel A AE temporal data. Slow vs fast titration compared at matched final maintenance dose for both 4 mg and 8 mg cohorts; waist-circumference-to-weight-loss ratios at week 4 used as quasi-DEXA proxy for fat-vs-lean distribution.

¹¹ Adaptation pathways (brainstem nausea circuit, sinus-node baroreflex) respond to rate of change in receptor occupancy; efficacy pathways respond to cumulative exposure over time. This is why slow titration produces fewer side effects at the same final dose.

¹² Coskun T, et al. Retatrutide discovery and receptor pharmacology. Cell Metabolism 2022: 10.1016/j.cmet.2022.07.002 — receptor binding constants (GIP EC50 0.0643 nM, GLP-1 0.775 nM, glucagon 5.79 nM); potency ratios vs native peptide (GIP 8.9× more potent than native, GLP-1 2.5× less potent, glucagon 2.9× less potent); full agonist at all three at cAMP signaling (E_max numbers in ref ¹⁵); 6-day half-life; structural design. Earlier framings of these numbers as "intrinsic efficacy multipliers" or "partial agonist" were a measurement-mislabel and are retracted.

¹³ T3 suppression on GLP-1 / GIP / glucagon agonism — caloric deficit and hepatic energy expenditure together downregulate T4-to-T3 conversion; Free T3 drops while TSH stays in range. See GLP-1 fatigue guide for monitoring.

¹⁴ Cross-class GIPR engagement comparison — retatrutide GIPR EC50 0.0643 nM (Coskun 2022) vs tirzepatide GIPR EC50 1.01 nM (Willard FS, et al. JCI Insight 2020;5(17): 10.1172/jci.insight.140532). Retatrutide's binding constant is 16× tighter — meaningful engagement happens at a fraction of tirzepatide's dose. At 1 mg, retatrutide engages 47% of GIP receptors; tirzepatide reaches 41% only at 15 mg. Both compounds are full agonists at GIPR cAMP signaling; once engaged, each receptor fires at native-equivalent peak strength.

¹⁵ Coskun 2022 mmc1 Table S1 + Table S2 — receptor functional activity at cAMP signaling. Retatrutide E_max at GIPR 103%, GLP-1R 110%, GCGR 104% of native peptide peak (full agonist at all three at cAMP signaling per the conclusions section: "LY3437943 is a full agonist at the GCGR, GIPR, and GLP-1R in the functional assays"). At a separate β-arrestin recruitment pathway at GLP-1R, reta E_max = 40% of native (partial / biased agonism), tirzepatide partial in the same direction, semaglutide full at both pathways. Earlier framings of "0.34× partial agonist at GCGR" or "0.4× softened agonist at GLP-1R" mistook potency ratios (EC50_LY ÷ EC50_native) for efficacy multipliers (E_max_LY ÷ E_max_native) and are retracted.

¹⁶ Coskun 2022 mmc3 Table 3 + mmc1 Table S8 — Phase 1 single-ascending-dose study (NCT03841630, n=45, conducted in Singapore). Population: 97.8% Asian, 93% male, mean weight 76.7 kg, mean BMI 26.3, healthy non-diabetic. Per-cohort baseline weight + BMI: 0.3 mg cohort 67.5 kg / BMI 23.2; 1 mg cohort 73.5 kg / BMI 26.1; 4.5 mg cohort 69.9 kg / BMI 23.2 (the leanest cohorts). Pulse rate 8-day average LSM CFB: placebo +5.0; 0.1 mg +2.4; 0.3 mg +7.6; 1 mg +10.3; 3 mg +16.7; 4.5 mg +25.2; 6 mg +19.3 (3 mg and above statistically significant vs placebo). Day 4–6 peak (Figure S4C) approximately 1.5–2× higher than the 8-day average. Returns toward baseline by day 29–43.

¹⁷ Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol 2024;13:494–503: 10.1002/psp4.13099. 39,644 samples, 5,802 participants, 19 studies. Two-compartment model with first-order absorption + elimination; F = 0.8 fixed; ka = 0.0373 /h; TVCL = 0.0329 L/h/70 kg; allometric exponent on CL = 0.8 (BW^0.8); allometric exponent on Vd = 1.0 with FFM + 0.482·FM scaling; mean t½ = 5.4 days; accumulation R at QW = 1.7×. Used as donor PopPK structure for the retatrutide PK bridge — the BW^0.8 allometric exponent is internally validated against retatrutide in Rosenstock 2023 arm pairs (4 mg ID2 at 108.3 kg vs 4 mg ID4 at 93.1 kg: predicted Cav,ss ratio 1.13, observed 1.18, 4.8% error), so the borrowing is tirz-prior, reta-confirmed rather than tirz-substituted.

¹⁸ Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. NEJM 2011;365:1597–1604: 10.1056/NEJMoa1105816. One year after diet-induced weight loss of about 13.5 kg, leptin remained 35% below baseline; ghrelin elevated; PYY suppressed; CCK suppressed; postprandial insulin reduced; hunger sustained above baseline. The hormonal adaptation pattern that drives regain is a 12-month story, not a transient.

¹⁹ Sinoatrial node chronotropy — direct Gs/cAMP/funny-channel signaling via GLP-1R at the heart's pacemaker. Lubberding AF, et al. Cardiovasc Res 2024 (direct mechanism demonstration); Petersen JD, et al. JAHA 2020 (esmolol crossover RCT confirming β-blockade independent and HRV unchanged — sympathetic activation is not the mediator). Pyke C, et al. 2014 monoclonal antibody localization confirms cardiac GLP-1R expression in human myocardium and SA node.

²⁰ Multi-receptor composite chronotropy — Goodman ML, et al. Br J Clin Pharmacol 2025 demonstrates that co-infusing a GLP-1 agonist with glucagon produces a perfectly additive HR response (+4 bpm + +4 bpm = +7 bpm at 60 min in n=12 lean males), confirming that glucagon drives chronotropy via a parallel pathway independent of GLP-1R cross-reactivity. For retatrutide at clinical doses, GLP-1R provides the baseline incretin HR rise (2–3 bpm); sparse but functional cardiac GCGR engagement drives the dose-scaling excess (3–6 bpm) unique to this class.

²¹ Local inhibitory network — GIPR-expressing neurons in the dorsal vagal complex (AP/NTS) are predominantly GABAergic with Gad1/Gad2 co-expression. Hayes MR, Borner T, De Jonghe BC. Diabetes 2021 + Zhang Q, et al. Neuron 2021 + Ludwig MQ, et al. Nat Metab 2021 (single-nuclei RNA-seq). Mechanism: GIPR activation → GABA release → local inhibition of GLP-1R-mediated emetic output. The brake circuit requires Hebbian synaptic plasticity to establish — neurons need to fire together at low intensity over time for the inhibitory connections to wire in. Fast titration skips this window. Cross-species emesis-blocking confirmed in musk shrew (Geisler/Borner 2020) and beagle + ferret (Takeda WO 2018/181864 A1).

²² Distinct cascade transduction states — Petersen JD, Sullivan TM. JCEM 2018 literature review documenting cardiac Gi-coupling shift in cardiomyocytes under chronic metabolic dysfunction. Obese sedentary cohorts show partial neutralization of Gs-driven chronotropy by upregulated Gi coupling, producing a fundamentally different Hill curve than the intact-Gs signaling of lean responsive cohorts. Same drug, same receptor occupancy, different cascade output. Confirmed by FDA NDA 215866 tirzepatide Clinical Pharmacology Review showing Japanese lean cohort amplified HR sensitivity at matched exposure.

²³ Adaptive thermogenesis offset — Long JZ, et al. 2025 demonstrates that chronic GCGR agonism downregulates hepatocyte PDE4B/4D phosphodiesterases, producing sustained cAMP-PKA signaling that preserves resting energy expenditure against the adaptive decline of weight loss. The mechanism is obesity-specific in mice; lean DIO mice show no GCGR-driven EE elevation. The practical claim is preservation against adaptive thermogenesis decline rather than baseline EE elevation. The chronic-tonic regime produces signals the pulsed regime cannot.

²⁴ Protein-leucine threshold for muscle protein synthesis — Mozaffarian D, et al. AJCN 2025 protein distribution and leucine threshold work. ≥1.6 g/kg/day total protein with ≥3 g leucine per meal across 3–4 meals optimizes muscle protein synthesis during caloric deficit.

²⁵ Tesamorelin pulsatile GH release — Stanley TL, et al. Tesamorelin for HIV-associated lipodystrophy. Lancet HIV 2019. Pulsatile growth-hormone release reduces visceral adipose tissue and liver fat.

²⁶ MOTS-c AMPK activation — Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015. MOTS-c activates AMPK, the cellular energy sensor that responds to exercise.